Article info

Download PDFPDF

Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment

Authors

  1. a sjohn2{at}health.usf.edu
  2. b scott.antonia{at}moffitt.org
  3. c trevor.rose{at}moffitt.org
  4. d rseifert{at}health.usf.edu
  5. e Barbara.Centeno{at}moffitt.org
  6. f brainpathology{at}gmail.com
  7. g 813.745.3050 ben.creelan{at}moffitt.org
View Full Text

Citation

John S, Antonia SJ, Rose TA, et al
Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment

Publication history

  • Received October 11, 2016
  • Accepted June 14, 2017
  • First published July 18, 2017.
Online issue publication 
July 18, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.